For the quarter ending 2026-03-31, EXOZ had -$1,594,781 decrease in cash & cash equivalents over the period. -$1,582,045 in free cash flow.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss | -2,370,247 | -2,655,036 | -2,286,991 | -4,216,707 |
| Amortization of deferred grant reimbursement | -11,992 | -12,700 | -13,055 | -27,158 |
| Depreciation of property and equipment | 74,147 | 73,599 | 71,603 | 142,759 |
| Non-cash lease expense | 20,897 | 15,503 | 23,235 | 14,629 |
| Tax payable | - | - | - | 0 |
| Stock-based compensation | 501,098 | 677,866 | 425,708 | 884,531 |
| Grants receivable | -214,496 | 214,716 | 45,236 | -479,875 |
| Prepaid expenses and other current assets | -40,341 | 184,166 | -88,699 | -76,371 |
| Tax receivable | - | -621 | 105,826 | - |
| Accounts payable and accrued expenses | -1,257 | 330,984 | -26,276 | 6,377 |
| Due to related party | 8,076 | -5,755 | 11,431 | -32,209 |
| Net cash (used in) operating activities | -1,524,441 | -1,973,800 | -1,856,708 | -2,671,532 |
| Deferred grant reimbursement | - | -2 | 2 | 19,699 |
| Purchases of property and equipment | 57,604 | 74,988 | 13,310 | 81,619 |
| Net cash (used in) investing activities | -57,604 | -74,990 | -13,308 | -61,920 |
| Related party note | - | - | - | 0 |
| Deferred ipo cost | - | - | - | 0 |
| Payments on finance lease obligations | 12,736 | 10,554 | 17,155 | - |
| Net cash (used in) financing activities | -12,736 | -10,554 | -17,155 | 0 |
| Net increase (decrease) in cash, cash equivalents | -1,594,781 | -2,059,344 | -1,887,171 | -2,733,452 |
| Cash and cash equivalents - beginning of period | 3,039,343 | 5,098,687 | 9,719,310 | - |
| Cash and cash equivalents - end of period | 1,444,562 | 3,039,343 | 5,098,687 | - |
EXOZYMES INC. (EXOZ)
EXOZYMES INC. (EXOZ)